

**TERMINAL DISCLAIMER**

The undersigned of Genencor International, Inc., Palo Alto, California 94304 (the successor to all rights of Genencor, Inc., a wholly owned subsidiary of Genencor International, Inc.), represents that Genencor International, Inc. is the assigned and exclusive owner of the entire right, title and interest of, in and to U.S. Patent Application Serial No. 10/719,571 indicated by the Assignment.


Genencor International, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of U.S. Patent No. 6,365,410 filed on May 19, 1999 and U.S. Patent No. 6,706,503 filed on October 23, 2001, also assigned to and owned by Genencor International, Inc., as indicated by the assignment records (Reel 010780, Frame 0498) of the U.S. Patent and Trademark Office, and hereby agrees that any patent so granted in the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the above-identified U.S. Patent, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

The undersigned has reviewed all the evidentiary documents referred to in the Terminal Disclaimer and it is certified to the best of the undersigned's knowledge and belief, title is in the Petitioner as described above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Petitioner.

Please charge the fee required by 37 CFR §1.20(d) to Deposit Account No. 07-1048.  
This document is submitted in triplicate.

Date: August 22, 2005

By:   
Christopher L. Stone

Title: Vice President and General Patent Counsel

08/24/2005 SSITHIB1 00000034 071048 10719571

01 FC:2814 65.00 DA

**TERMINAL DISCLAIMER**

The undersigned of Genencor International, Inc., Palo Alto, California 94304 (the successor to all rights of Genencor, Inc., a wholly owned subsidiary of Genencor International, Inc.), represents that Genencor International, Inc. is the assigned and exclusive owner of the entire right, title and interest of, in and to U.S. Patent Application Serial No. 10/719,571 indicated by the Assignment.


Genencor International, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of U.S. Patent No. 6,365,410 filed on May 19, 1999 and U.S. Patent No. 6,706,503 filed on October 23, 2001, also assigned to and owned by Genencor International, Inc., as indicated by the assignment records (Reel 010780, Frame 0498) of the U.S. Patent and Trademark Office, and hereby agrees that any patent so granted in the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the above-identified U.S. Patent, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

The undersigned has reviewed all the evidentiary documents referred to in the Terminal Disclaimer and it is certified to the best of the undersigned's knowledge and belief, title is in the Petitioner as described above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Petitioner.

Please charge the fee required by 37 CFR §1.20(d) to Deposit Account No. 07-1048.  
This document is submitted in triplicate.

Date: August 22, 2005

By:   
Christopher L. Stone

Title: Vice President and General Patent Counsel